NCT06003660 Oral, Chemosensory and Trigeminal Functions in Allo-HSCT
| NCT ID | NCT06003660 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oslo |
| Condition | Hematopoietic Stem Cell Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-08-10 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2023-08-10 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective, cohort study is to learn about smell, taste and trigeminal dysfunction in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). The research team hypothesizes that treatment with allo-HSCT will induce: * Distortion of taste and smell and trigeminal functions like cooling, tingling, and burning sensations. * Reduced saliva production leading to oral dryness and dental caries. * Changes in the connectivity of the taste-, smell- and pain-cortical brain regions.
Eligibility Criteria
Inclusion Criteria: • patients receiving myeloablative conditioning for a first-time allo-HSCT and diagnosed with either a leukemia or a myelodysplastic syndrome Exclusion Criteria: * disorders affecting the oral cavity including poor tooth-status * those using drugs affecting the gustatory/olfactory functions * those with brain disorders * those who have a chronic disorder affecting the immune system, have cancer or who are pregnant.
Contact & Investigator
Per Ole Iversen, phd
STUDY DIRECTOR
University of Oslo
Frequently Asked Questions
Who can join the NCT06003660 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06003660 currently recruiting?
Yes, NCT06003660 is actively recruiting participants. Contact the research team at p.o.iversen@medisin.uio.no for enrollment information.
Where is the NCT06003660 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT06003660 clinical trial?
NCT06003660 is sponsored by University of Oslo. The principal investigator is Per Ole Iversen, phd at University of Oslo. The trial plans to enroll 70 participants.